ストックスクリーナーアプリを入手
4.035
1.64%
0.065
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - Sahm
Eledon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ELDN) - TradingView
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - BioSpace
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Nigeria
Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
NEWSLETTER: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial - Reuters
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney TransplantationSlideshow (NASDAQ:ELDN) 2026-06-22 - Seeking Alpha
Eledon Pharmaceuticals Amends Certificate of Incorporation – Key Changes Filed in 8-K SEC Report - Minichart
Leerink raises Eledon Pharmaceuticals price target on trial data - Investing.com
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Eledon reports Phase 2 BESTOW kidney transplant data - grafa.com
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation - marketscreener.com
Eledon Pharmaceuticals (ELDN) Presents Promising Phase 2 BESTOW Study Data - GuruFocus
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data - Investing.com South Africa
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus - marketscreener.com
Eledon reports kidney function benefit for tegoprubart at 18 months - Investing.com
Eledon reports kidney function benefit for tegoprubart at 18 months By Investing.com - Investing.com South Africa
Eledon Presents Long-Term Extension Phase 2 BESTOW Results - GlobeNewswire
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Nigeria
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Is Eledon Pharmaceuticals (ELDN) outperforming other medical stocks this year? - MSN
Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
Noble Financial Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com Nigeria
1.53%
3.59%
大文字化:
|
ボリューム (24 時間):